Compare STRIDES PHARMA SCIENCE with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs DR. REDDYS LAB - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE DR. REDDYS LAB STRIDES PHARMA SCIENCE/
DR. REDDYS LAB
 
P/E (TTM) x 41.5 40.5 102.5% View Chart
P/BV x 1.9 5.5 35.0% View Chart
Dividend Yield % 0.3 0.5 52.3%  

Financials

 STRIDES PHARMA SCIENCE   DR. REDDYS LAB
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
DR. REDDYS LAB
Mar-20
STRIDES PHARMA SCIENCE/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,1473,363 34.1%   
Low Rs6422,352 27.3%   
Sales per share (Unadj.) Rs317.21,054.2 30.1%  
Earnings per share (Unadj.) Rs7.8121.9 6.4%  
Cash flow per share (Unadj.) Rs25.1190.2 13.2%  
Dividends per share (Unadj.) Rs2.0025.00 8.0%  
Dividend yield (eoy) %0.20.9 25.6%  
Book value per share (Unadj.) Rs274.3938.7 29.2%  
Shares outstanding (eoy) m89.50166.17 53.9%   
Bonus / Rights / Conversions ESOPESOP-  
Price / Sales ratio x2.82.7 104.0%   
Avg P/E ratio x114.023.4 486.5%  
P/CF ratio (eoy) x35.715.0 237.6%  
Price / Book Value ratio x3.33.0 107.1%  
Dividend payout %25.520.5 124.3%   
Avg Mkt Cap Rs m80,058474,831 16.9%   
No. of employees `0002.521.7 11.6%   
Total wages/salary Rs m4,34133,802 12.8%   
Avg. sales/employee Rs Th11,325.88,091.0 140.0%   
Avg. wages/employee Rs Th1,731.41,561.3 110.9%   
Avg. net profit/employee Rs Th280.1935.8 29.9%   
INCOME DATA
Net Sales Rs m28,394175,170 16.2%  
Other income Rs m9416,206 15.2%   
Total revenues Rs m29,334181,376 16.2%   
Gross profit Rs m3,96524,421 16.2%  
Depreciation Rs m1,54011,348 13.6%   
Interest Rs m1,962983 199.6%   
Profit before tax Rs m1,40318,296 7.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-168561 -29.9%   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97-1,403 -6.9%   
Profit after tax Rs m70220,260 3.5%  
Gross profit margin %14.013.9 100.2%  
Effective tax rate %6.9-7.7 -90.4%   
Net profit margin %2.511.6 21.4%  
BALANCE SHEET DATA
Current assets Rs m24,836125,991 19.7%   
Current liabilities Rs m18,99372,141 26.3%   
Net working cap to sales %20.630.7 66.9%  
Current ratio x1.31.7 74.9%  
Inventory Days Days7173 97.1%  
Debtors Days Days113105 108.2%  
Net fixed assets Rs m34,28983,854 40.9%   
Share capital Rs m895831 107.7%   
"Free" reserves Rs m23,651155,157 15.2%   
Net worth Rs m24,546155,988 15.7%   
Long term debt Rs m15,5131,304 1,189.7%   
Total assets Rs m65,437232,253 28.2%  
Interest coverage x1.719.6 8.7%   
Debt to equity ratio x0.60 7,560.3%  
Sales to assets ratio x0.40.8 57.5%   
Return on assets %4.19.1 44.5%  
Return on equity %2.913.0 22.0%  
Return on capital %6.912.6 54.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69784,193 18.6%   
Fx outflow Rs m73539,616 1.9%   
Net fx Rs m14,96244,577 33.6%   
CASH FLOW
From Operations Rs m1,87129,841 6.3%  
From Investments Rs m5,826-4,923 -118.3%  
From Financial Activity Rs m-10,157-25,159 40.4%  
Net Cashflow Rs m-2,615-266 983.0%  

Share Holding

Indian Promoters % 27.7 25.5 108.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 5.4 700.0%  
FIIs % 8.6 35.3 24.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 25.9 15.3 169.3%  
Shareholders   56,241 75,885 74.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Down 100 Points, Bharti Airtel Q4 Performance, Spot Gold Exchange Framework, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note yesterday. Benchmark indices continued their positive momentum for the second consecutive day.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 18, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - JUBILANT PHARMOVA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS